Effects of low-molecular-weight heparin on lung and pulmonary artery injuries in acute pulmonary embolism rat model via platelet-derived growth factor-B

Yunjian Zhang¹, Weihua Zhang², Xiaofang Wang¹, Chunping Liu³, Jvhong Shi⁴, Weixuan Lu⁴

¹Department of Medicine and Division of Pulmonary and Critical Care Medicine, Jishuitan Hospital, Fourth Medical College of Peking University, China; ²Center of International Medicine, Chinese PLA General Hospital, China; ³Department of Medicine and Division of Cardiology, General Hospital of Beijing Military Command, China; ⁴Department of Medicine and Division of Pulmonary Medicine, Peking Union Medical College Hospital, Chinese Academy of Medicine Science and Peking Union Medical College, China

Received March 9, 2016; Accepted May 25, 2016; Epub July 1, 2016; Published July 15, 2016

Abstract: Objective: To evaluate the effects of anticoagulant agent (low-molecular-weight heparin, LMWH) on the pulmonary artery intima hyperplasia of rats with acute pulmonary embolism (APE) by assaying platelet-derived growth factor-B (PDGF-B). Methods: A total of 90 Sprague-Dawley rats were randomly assigned into the sham, APE, and LMWH groups with 30 rats in each group. The APE rat models were established by injecting autologous blood clots via external jugular veins. In each group, six rats were sacrificed at the 1st day (D1), 4th day (D4), 7th day (D7), 14th day (D14), and 28th (D28) subsequent to the induction of APE to collect the lungs. Right ventricle pressure (RVP) and mean pulmonary arterial pressure (mPAP) were measured. Western blot and RT-PCR analyses were used to assess PDGF-B expression at various time points. In addition, changes in lung pathology were evaluated using hematoxylin and eosin (H&E) staining and electron microscope. Results: The overall success rate of establishing APE rat models was 85.7% (60/70). There was no difference in mPAP between the sham group and the APE group at the D1, D4, D7, and D14. However, at the D28, mPAP in the APE group was higher than that in the sham group. Although it did not reach significant level (P = 0.08). There was no difference among the three groups regarding RVP. PDGF-B expression were decreased in the LMWH group at all time points compared with the sham and APE groups (P < 0.01). Furthermore, pulmonary embolism, alveolar wall necrosis and hemorrhage, and inflammation were significantly attenuated in the LMWH group compared with the sham and APE groups subsequent to the induction of APE. Conclusion: LMWH attenuates lung and pulmonary artery injuries and improves prognosis. Decreased PDGF-B in the lungs may be the important factor in the effects observed.

Keywords: Low molecular weight heparin (LMWH), acute pulmonary embolism (APE), platelet-derived growth factor-B (PDGF-B)

Introduction

Acute pulmonary embolism (APE) is a common cause of pulmonary hypertension (PH) contributing to right heart failure which has a high rate of mortality [1]. Traditionally, the degree of mechanical obstruction of the pulmonary vascular by embolic thrombi was considered to be the major determinant of the increase in PH [2]. However, it has been recently shown that pulmonary vascular reconstruction in response to APE whose mechanism is mainly migration of vascular smooth muscle cells (SMCs) to the pulmonary artery intima and proliferation under the influence of cytokines [3]. It has been shown that heparin and low molecular weight heparin (LMWH) have resistant effects against SMC proliferation [4-6]. Therefore we hypothesize that LMWH might be able to inhibit pulmonary artery intima hyperplasia. The objective of this study is to determine if APE and pulmonary artery intima hyperplasia are affected by LMWH.

Materials and methods

Materials and experimental animals

Experimental animals: A total of 90 male Sprague-Dawley rats weighting 250±20 g were
Effects of LMWH on lung and pulmonary artery injuries

purchased from Institute of Laboratory Animals of Chinese Academy of Medical Science. The mice were kept in Laboratory Animal Center of Peking Union Hospital and had free access to water and food. Those mice were randomly divided into the sham operation group, acute pulmonary embolism (APE) group, and low molecular heparin (LMWH) treatment group, with 30 rats in each group. 30 rats in each group were further divided into the 1st day (D1), the 4th day (D4), the 7th day (D7), the 14th day (D14), and the 28th (D28), with 6 mice in each group.

The major instruments and reagents: Cmias 2001B multifunctional color pathological image analysis system (Beihang University, China); IM1000 ECG monitor (COULD Inc, the United States); JE M1010 transmission electron microscopy (TEM) (JEOL Inc, Japan); Twin Block PCR thermal cycle system (ERICOMP Inc, the United States); GAA7001B gel image analysis system (UVI Inc, the United Kingdom). Fraxiparine (Low-Molecular-Weight Heparin Sodium Injection, 9500 IU anti-Xa/ml according to European Pharmacopoeia, Sanofi Pharma, France). Rabbit anti-rat PDGF-B polyclonal antibody (Wuhan Boster Biotechnology Company, China).

Methods

Establishment of rat APE model: The APE model was produced using the autologous blood clot method. Briefly, blood was drawn from the tail veins of the rats. After coagulation, blood clots were in 70°C water bath for 10 minutes and then cut into a size of 1.1 mm × 2 mm. 25 autologous blood clots followed by 2 ml normal saline were injected into the external jugular vein. The successful establishment of the rat APE model was indicated by the symptom of shortness of breath. In the mean time, the rats in the sham group were injected the same amount of normal saline. At the 24 hours post-operation, rats in the LMWH treatment group were given subcutaneous injection of LMWH (Fraxiparine, 0.01 ml/Kg), Q12 h, for 14 consecutive days. Rats in the sham and APE groups were given subcutaneous injection of the same amount of normal saline. All the rats had free access to water and food after operation.

Measurement of right ventricle pressure (RVP) and mean pulmonary arterial pressure (mPAP): A cannula was inserted into the pulmonary artery via the right ventricle, and a tight ligature was placed around the main trunk of pulmonary artery. The lungs were perfused with a peristaltic pump (Incibras, Sao Paulo, Brazil; 9 mL/min), and pulmonary venous outflow was diverted into a reservoir via a cannula that was inserted in the left atrium through the left ventricle and fixed with a ligature at the apex of the heart. Another ligature was placed above the atrioventricular junction to prevent the perfusate mixture from flowing into the ventricles. The perfusate mixture was maintained at 37°C by a heat exchanger. Mean pulmonary arterial pressure was measured from a side arm of the inflow cannula with pressure transducers (COBE, Arvada, CO) zeroed at the level of pulmonary artery cannula.

Expression of SMCs and PDGF-B in lung tissues: After the model was established, six rats from each group were anesthetized with intramuscular 10% chloral hydrate solution at the 1st day (D1), the 4th day (D4), the 7th day (D7), the 14th day (D14), and the 28th (D28). Next, the lung tissues were quickly removed, and a small piece of the lung was routinely embedded in paraffin and used for immunohistochemical staining of SMCs and PDGF-B. Four lung sections from each rat were analyzed, and three high-magnification fields of vision were randomly selected from each section, and the mean was calculated. The lung tissues in each group were fixed with 10% formaldehyde for 24 hours. Paraffin-embedded sections were cut into slices, stained with hematoxylin-eosin, and analyzed by experienced pathologists under an optical microscope.

Measurement of pulmonary vessels: Five cross sections of pulmonary artery was selected for each mouse. Cmias2001B multifunctional true color pathological image analysis system was used to measure the vessel tube areas, lumen areas, wall areas, tube diameters, wall thickness, wall area to tube area ratios, lumen area to tube area ratios, vessel wall thickness, and vessel diameters. In order to make the size of the pulmonary artery not affect the comparison, wall area to tube area ratios and vessel wall thickness to tube diameter rations were selected as statistical indexes.

Measurement of PDGF-B protein expression in lung tissues: The upper lobes of the left lung were collected for the detection of PDGF-B pro-
Effects of LMWH on lung and pulmonary artery injuries

tein expression by Western blot analysis. The optical intensity of the visualization signal was analyzed using an ImageJ densitometric analysis system (National Institutes of Health, Bethesda, MD, USA), and PDGF-B protein expression was normalized to β-actin.

Measurement of PDGF-B mRNA expression in lung tissues: RNA was extracted from lung tissues; PDGF-B was amplified using RT-PCR. PCR primers (Shanghai Sangon biotech company, Shanghai, China) included rat β-actin upstream primer 5’ CCA AGG CCA ACC GCG AGA TGA C 3’, downstream primer 5’ AGG GTA CAT GGT GCC GCC AGA C 3’. PCR product length was 587 bp; rat PDGF-β upstream primer 5’ GAT CCG CTC CTT TGA TGA TC 3’, downstream primer 5’ GTC TCA CAC TTG CAT GCC AG 3’, PCR product length was 435 bp.

PCR amplified products underwent 2% agarose gel electrophoresis and was scanned by UVI gel image scan and analyze system using UVIsoft and Application V97.04 analysis software.

Statistical analysis

Statistical analysis was performed using SPSS 13.0. The data were expressed as the mean ± standard deviation (SD). Differences were analyzed by one-way analysis of variance (ANOVA) followed by the Newman-Keuls test; values of $P < 0.05$ were considered statistically significant.

Results

Establishment of rat APE model

A total of 70 rats were injected with autologus clot. Two rats died during anesthesia. Two rats died during injection. Four and two rats died 1 and 3 hours post-injection respectively. Therefore, there were 60 rat APE models established. The success rate was 85.7%. All rats had shortness of breath, cyanosis, and increased heart rate after injection.

Measurement of RVP and mPAP

There was no difference in mPAP between the sham group and the APE group at the D1, D4, D7, and D14. However, at the D28, mPAP in the APE group was higher than that in the sham group. Although it did not reach significant level ($33.17±7.99$ vs. $24.80±5.54$ mmHg, $P = 0.08$) (Figure 1A). Regarding RVP, there were no differences among the three groups (Figure 1B).

Lung tissue pathology and pulmonary artery changes

In the sham group, the pulmonary vascular structure was normal. There was no bleeding and exudation in alveolar and no inflammatory cell infiltration in alveolar septum. At the D1, there were visible emboli and secondary thrombosis found in pulmonary arteries in the APE group. At the D4, there was partial dissolution of thrombus and a lot of white blood cells accumulated (Figure 2); At the D7, most thrombi were dissolved, a few of them which did not dissolve had polymorphonuclear cells and macrophages infiltration and angiogenesis; At the D14, only a few thrombi were not dissolved; At the D28, all thrombi were completely dissolved. Pulmonary artery intima occurred hyperplasia from the D4 until the D28. There was severe vascular stenosis (Figure 2); At the D1, there were a lot of alveolus exudation and infiltration of inflammatory cells in alveolar septa; At the D4 and D7, alveolar edema was relieved. But there were still a large number of inflammatory cells accumulated in alveolar septa; At the D14 and D28, alveolar structure was basically normal. Interstitial inflammatory cells decreased,
but were still more than that in the sham group. The pulmonary artery intimal hyperplasia and vascular stenosis were much less in the LMWH group than the APE group; at the D1, alveolar exudation and interstitial inflammatory cell infiltration in the LMWH group were very similar with the APE group. At the D4, alveolar exudation was not obvious. There was still infiltration of inflammatory cells in alveolar septa, which was less severe than the APE group. The pulmonary artery wall area to tube area ratios and wall thickness to tube diameter ratios are shown in the Tables 1 and 2.

**Table 1.** Wall area/tube area ratios among the three groups (\( \bar{x} \pm s \))

<table>
<thead>
<tr>
<th></th>
<th>( d_1 ) (n = 6)</th>
<th>( d_4 ) (n = 6)</th>
<th>( d_7 ) (n = 6)</th>
<th>( d_14 ) (n = 6)</th>
<th>( d_28 ) (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>0.68±0.15</td>
<td>0.65±0.08</td>
<td>0.63±0.02</td>
<td>0.60±0.08</td>
<td>0.56±0.03</td>
</tr>
<tr>
<td>APE</td>
<td>0.65±0.12</td>
<td>0.78±0.07*</td>
<td>0.71±0.03*</td>
<td>0.71±0.07*</td>
<td>0.61±0.03*</td>
</tr>
<tr>
<td>LMWH</td>
<td>0.52±0.03</td>
<td>0.68±0.09*</td>
<td>0.64±0.06*</td>
<td>0.55±0.11*</td>
<td>0.52±0.05*</td>
</tr>
</tbody>
</table>

*P < 0.05 APE vs. sham, *P < 0.05 LMWH vs. APE.

**Table 2.** Wall thickness/tube diameter ratios among the three groups (\( \bar{x} \pm s \))

<table>
<thead>
<tr>
<th></th>
<th>( d_1 ) (n = 6)</th>
<th>( d_4 ) (n = 6)</th>
<th>( d_7 ) (n = 6)</th>
<th>( d_14 ) (n = 6)</th>
<th>( d_28 ) (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>0.39±0.10</td>
<td>0.31±0.01</td>
<td>0.35±0.04</td>
<td>0.34±0.06</td>
<td>0.30±0.02</td>
</tr>
<tr>
<td>APE</td>
<td>0.40±0.10</td>
<td>0.50±0.10*</td>
<td>0.42±0.04*</td>
<td>0.43±0.05*</td>
<td>0.35±0.03*</td>
</tr>
<tr>
<td>LMWH</td>
<td>0.30±0.03</td>
<td>0.40±0.05*</td>
<td>0.36±0.04*</td>
<td>0.31±0.09*</td>
<td>0.28±0.04*</td>
</tr>
</tbody>
</table>

*P < 0.05 APE vs. sham, *P < 0.05 LMWH vs. APE.

There were very few organelles in the cytoplasm. The pulmonary artery SMCs in the PTE group were dumbbell-shaped. The cytoplasm was abundant. The muscle fiber was decreased. And some of the vacuoles were degenerated (Figure 3A). The morphology of pulmonary artery SMCs in the LMWH group was normal (Figure 3B).

**PDGF-B immunohistochemistry results**

PDGF-B was primarily expressed in the pulmonary artery SMCs. A small amount of it was expressed in alveolar macrophages. There was no expression in the pulmonary vascular endothelial cells. The expression reached the peak at the 4th day after pulmonary embolism (Figure 4A) and gradually decreased after one week. There was a small amount of PDGF-B expression in the pulmonary artery of the sham group, but no expression in the lung tissue at all.

**PDGF-B protein expression in lung tissues**

There was significant increase of PDGF-B protein expression from the 1st to the 14th day after pulmonary embolism which actually reached its peak at the 7th day (P < 0.05). The expression level at the 28th day was similar with that of the sham group. The expression levels in the LMWH
Effects of LMWH on lung and pulmonary artery injuries

Figure 3. The images from electron microscope. A. 14 days after APE, the nucleoli of pulmonary artery smooth muscle cells enlarged, cytoplasm was abundant. Rough endoplasmic reticulum and mitochondria increased. Part of the vacuolar degenerated. ×6000; B. 14 days after APE, pulmonary artery SMCs morphology was normal in the LMWH group ×5000.
Effects of LMWH on lung and pulmonary artery injuries

**Figure 4.** Expression of PDGF-B. A. 4 days after APE, there were a lot of PDGF-B expression in pulmonary artery wall. ×400; B. Expression in the sham and APE groups at the different time points. Expression in the LMWH and PTE groups at the different time points. M, S, P, L represent DNA marker, Sham, APE, and LMWH respectively 1, 4, 7, 14, 28 represent the days post pulmonary embolism. *P < 0.05 PTE vs. sham; #P < 0.05 LMWH vs. PTE; ΔP < 0.05 LMWH vs. sham; C. Expression of PDGF-B protein in the LMWH and PTE groups. *P < 0.05 PTE vs. sham; #P < 0.05 LMWH vs. PTE; ΔP < 0.05 LMWH vs. PTE; D. Expression of PDGF-B mRNA among the three groups, *P < 0.05 PTE vs. sham, **P < 0.01 PTE vs. sham; #P < 0.05 LMWH vs. PTE; ΔP < 0.05 LMWH vs. sham.

Group were less than the APE group at the 4th, 7th, and 14th days (P < 0.05), but were still more than the sham group (P < 0.05) (Figure 4C).

**PDGF-B mRNA expression in lung tissues**

There was a small amount of PDGF-B mRNA expression in lung tissue of the sham group. The expression was significantly increased in the APE group and reached the peak 4 days after pulmonary embolism (P < 0.01) but decreased at the 7th and 14th days which were still higher than the sham group (P < 0.05) until the 28th day. PDGF-B mRNA expression in the LMWH group declined at the 4th, 7th, and 14th days compared with the APE group (P < 0.05) (Figure 4B and 4D).

**Discussion**

This study used autologous blood clot method to establish the rat pulmonary embolism model which had several advantages including small trauma, fixed embolus size and number to guarantee the success and stability of the APE model. The success rate of our method was 85.7% which demonstrated that it was a successful method.

Without underlying lung diseases, the blocking area of pulmonary vascular bed is strongly correlated with mPAP, RVP, and PaO2 [7]. In general, when 25%~30% pulmonary vascular bed is blocked, mPAP rises in certain degree; when 50% pulmonary vascular bed is blocked, mPAP rises significantly; when 75% pulmonary vascular bed is blocked, mPAP will rise to result in right heart failure [8]. In our experiment, the average mPAP was not increased significantly due to relatively small blocked area of pulmonary vascular bed and relatively good cardio-pulmonary function of rats at the baseline. Although the pathology showed that there was pulmonary artery intimal hyperplasia 28 days after pulmonary embolism, mPAP does not rise significantly suggesting the pulmonary artery intima hyperplasia caused by pulmonary vascular remodeling after an acute embolism events does not play a major role in the formation of pulmonary hypertension. To the contrary, recurrence of pulmonary embolism and incomplete dissolution of some embolus resulting in pulmonary vascular reconstruction is the key factors that lead to chronic pulmonary hypertension.

Eagleton, et al [9] found that neutrophils infiltrated the pulmonary artery wall beginning at 3 hours after APE, peaked at 2 days, and returned to baseline by 8 days after APE. Macrophage accumulation peaked at 1 day after APE and returned to baseline by 4 days after APE. APE was also associated with a significant pulmonary artery intimal hyperplasia which was apparent at 4 days after APE and persisting through 14 days [10]. In our study, we found that white blood cells including neutrophils and macrophages infiltrated pulmonary wall beginning at 1 day after APE, gradually increased as embolus was dissolving, and was persistent by 7 days after APE, which was consistent with Eagleton and colleagues' results. In addition, we found that white blood cells was present not only in pulmonary artery wall and embolus but also in distant pulmonary tissues suggesting that PE-caused inflammation might be more general than expected.

Previous study showed that 66% patients had incomplete recovery of lung perfusion 3 months after APE which was even treated with antithrombotic agents. We hypothesize that pulmonary vascular reconstruction is the key factors that result in lung perfusion deficiency. Our study showed that compared to the sham group, the wall area/tube area ratio and wall thickness/tube diameter ratio of the PTE group were significantly higher, apparent at 4 days after APE and persisting through 28 days. After LMWH treatment, the wall area/tube area and wall thickness/tube diameter ratios were significantly decreased than the PTE group. The above findings showed that APE resulted in pulmonary artery intimal hyperplasia which was inhibited by LMWH.
Effects of LMWH on lung and pulmonary artery injuries

Vascular smooth muscle cells (VSMCs) phenotype has the characteristics of diversity and variability. This study found that pulmonary artery VSMCs translated from deflation phenotype to synthetic phenotype after APE, peaked at 14 days after APE. APE can cause release of a variety of cytokines and inflammatory mediators including TXA₂, AT II, PDGF, and bFGF etc. Under the stimulus of above factors, pulmonary artery smooth VSMCs migrate to intima and translate into synthetic phenotype. In addition, extracellular matrix deposition resulted in pulmonary artery intima hyperplasia. This study showed that LMWH can reduce the degree of pulmonary artery stenosis after APE suggesting LMWH inhibits the translation of pulmonary artery VSMCs from deflation phenotype to synthetic phenotype.

Studies have shown that PDGF is associated with hypoxic pulmonary VSMCs proliferation and post-PTCA restenosis. Haruno et al [11] found that arterial endothelium PDGF-B expression level significantly increased 14 days after balloon injury on rat artery. Our study showed that PDGF-B mRNA and protein expression levels significantly increased within 28 days after pulmonary embolism.

PDGF-B is primarily expressed by pulmonary artery VSMCs and alveolar macrophages. Tanizawa et al [12] reported that PDGF-B expression mainly is located in the α-actin negative spindle cells and macrophages at the early stage of post-PTCA. When the neointima was composed mainly of α-actin positive smooth muscle cells, PDGF-B expression significantly decreased. Our findings are consistent with the above results regarding the location and timeline of PDGF-B expression.

This study suggests that LMWH can reduce pulmonary artery intimal hyperplasia after APE, therefore has the anti-proliferation effects on VSMCs. This may be due to PDGF-B and thrombin promoting the proliferation of VSMCs. Rothman, et al [13] studied the effects of thrombin and PDGF on rat pulmonary arterial smooth muscle cell line (PAC1). Over 72 hrs, thrombin (1 unit/ml) resulted in 102±12% increase in protein synthesis per cell. PDGF stimulated proliferation as evidenced by an increase in cell number (doubling in 5 days). Therefore, thrombin caused cell hypertrophy while PDGF caused cell proliferation. They cooperate with each other to translate VSMCs from deflation phenotype to synthetic phenotype [14, 15].

In conclusion, this study found that rats had severe pulmonary artery intima hyperplasia 4-28 days after APE. The underlying mechanism might be increase of synthesis and release of cytokines including PDGF-B under whose influence VSMCs translate from deflation phenotype to synthetic phenotype resulting in neointimal formation. LMWH can inhibit PDGF-B mRNA and protein expression, thus improve hypoxemia after APE, and reduce the proliferation-promoting effects of PDGF-B on pulmonary artery VSMCs to inhibit pulmonary artery intimal hyperplasia after APE.

There are several limitations of this study. First of all, a lot of factors are involved in the formation of intima hyperplasia after APE. We only conducted preliminary studies on PDGF-B. Further studies should be done on other cytokines including MCP-1, ET-1, and AT II, etc. Second, due to the differences between species, the role of PDGF-B in the process in human pulmonary vascular remodeling might be different from it in rats. Therefore whether LMWH can inhibit pulmonary arterial intima hyperplasia in human being needs further investigation.

Acknowledgements

This work was supported by the Project of Beijing Municipal Science and Technology Commission (Z141107002514153).

Disclosure of conflict of interest

None.

Address correspondence to: Yunjian Zhang, Department of Medicine and Division of Pulmonary and Critical Care Medicine, Jishuitan Hospital, Fourth Medical College of Peking University, 31 East Xinjiekou Street, Xicheng District, Beijing 100035, China. Tel: +86-10-58516688-6842; E-mail: zhangyjian@126.com

References

Effects of LMWH on lung and pulmonary artery injuries


